Pliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by HC Wainwright

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]

Related Keywords

Canada ,United States ,Mike Ouimette ,Pliant Therapeutics Inc ,Needham Company ,Barclays Plc ,Royal Bank ,Mirae Asset Global Investments Co ,Silverarc Capital Management ,Wells Fargo Company ,Oppenheimer Co ,Securities Exchange Commission ,Pliant Therapeutics ,Get Free Report ,Therapeutics Trading Down ,Hans Hull ,Exchange Commission ,General Counsel Mike Ouimette ,Asset Global Investments ,Capital Management ,Partners Asset Management ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Reiterated Rating ,Hc Wainwright ,